FDA Approves New Treatments for Bladder Cancer
TL;DR Summary
The FDA has approved INLEXZO™, a new intravesical system for treating certain bladder cancers, offering a bladder-preserving option for patients unresponsive to BCG therapy, with promising clinical trial results showing high response rates and manageable safety profile.
- U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated Johnson & Johnson
- J&J’s Pretzel-Shaped Device Approved to Treat Bladder Cancer Bloomberg.com
- US FDA approves J&J's bladder cancer treatment yahoo.com
- Johnson & Johnson gains approval of gemcitabine for local delivery into bladder Seeking Alpha
- FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS OncLive
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
11 min
vs 11 min read
Condensed
98%
2,157 → 37 words
Want the full story? Read the original article
Read on Johnson & Johnson